中国癌症杂志
中國癌癥雜誌
중국암증잡지
CHINA ONCOLOGY
2009年
7期
503-507
,共5页
陈小兵%张军辉%董文杰%曹新广%罗素霞%索振河
陳小兵%張軍輝%董文傑%曹新廣%囉素霞%索振河
진소병%장군휘%동문걸%조신엄%라소하%색진하
结肠癌%靛玉红甲肟%增殖%凋亡%生存蛋白基因%bcl-2%Bax
結腸癌%靛玉紅甲肟%增殖%凋亡%生存蛋白基因%bcl-2%Bax
결장암%전옥홍갑우%증식%조망%생존단백기인%bcl-2%Bax
colon cancer%indirubin-3'-monoxime%proliferation%apoptosis%survivin%bcl-2%Bax
背景与目的:近年来有报道称靛玉红甲肟(indirubin-3'-monoxime)在体内外实验中对部分实体肿瘤细胞具有明显的抑制作用,但尚未见其对人结肠癌HT-29细胞影响的研究报道,因而本文旨在研究其对HT-29细胞增殖和凋亡的影响及其机制.方法:MTT法检测不同浓度靛玉红甲肟处理HT-29细胞后细胞的增殖活性,制作生长抑制曲线.流式细胞仪检测凋亡率,RT-PCR检测细胞凋亡抑制基因survivin和bcl-2及凋亡促进基因Bax mRNA的变化.结果:靛玉红甲肟明显的抑制HT-29的增殖,其作用表现为剂量依赖性和时间依赖性(F=11.25,P<0.01).流式细胞仪检测发现:以10 μ mol/L的靛玉红甲肟处理HT-29细胞后,其凋亡率呈时间依赖性上升(F=195.25,P<0.01).RT-PCR检测发现HT-29细胞survivin(F=78.75,P<0.01)和Box(F=87.61,P<0.01)转录上升,而bcl-2转录显著下降(F=95.82,P<0.01).结论:靛玉红甲肟对人结肠癌HT-29细胞具有明显的增殖抑制和诱导凋亡作用,其作用机制与下调bcl-2/Bax比例有关.
揹景與目的:近年來有報道稱靛玉紅甲肟(indirubin-3'-monoxime)在體內外實驗中對部分實體腫瘤細胞具有明顯的抑製作用,但尚未見其對人結腸癌HT-29細胞影響的研究報道,因而本文旨在研究其對HT-29細胞增殖和凋亡的影響及其機製.方法:MTT法檢測不同濃度靛玉紅甲肟處理HT-29細胞後細胞的增殖活性,製作生長抑製麯線.流式細胞儀檢測凋亡率,RT-PCR檢測細胞凋亡抑製基因survivin和bcl-2及凋亡促進基因Bax mRNA的變化.結果:靛玉紅甲肟明顯的抑製HT-29的增殖,其作用錶現為劑量依賴性和時間依賴性(F=11.25,P<0.01).流式細胞儀檢測髮現:以10 μ mol/L的靛玉紅甲肟處理HT-29細胞後,其凋亡率呈時間依賴性上升(F=195.25,P<0.01).RT-PCR檢測髮現HT-29細胞survivin(F=78.75,P<0.01)和Box(F=87.61,P<0.01)轉錄上升,而bcl-2轉錄顯著下降(F=95.82,P<0.01).結論:靛玉紅甲肟對人結腸癌HT-29細胞具有明顯的增殖抑製和誘導凋亡作用,其作用機製與下調bcl-2/Bax比例有關.
배경여목적:근년래유보도칭전옥홍갑우(indirubin-3'-monoxime)재체내외실험중대부분실체종류세포구유명현적억제작용,단상미견기대인결장암HT-29세포영향적연구보도,인이본문지재연구기대HT-29세포증식화조망적영향급기궤제.방법:MTT법검측불동농도전옥홍갑우처리HT-29세포후세포적증식활성,제작생장억제곡선.류식세포의검측조망솔,RT-PCR검측세포조망억제기인survivin화bcl-2급조망촉진기인Bax mRNA적변화.결과:전옥홍갑우명현적억제HT-29적증식,기작용표현위제량의뢰성화시간의뢰성(F=11.25,P<0.01).류식세포의검측발현:이10 μ mol/L적전옥홍갑우처리HT-29세포후,기조망솔정시간의뢰성상승(F=195.25,P<0.01).RT-PCR검측발현HT-29세포survivin(F=78.75,P<0.01)화Box(F=87.61,P<0.01)전록상승,이bcl-2전록현저하강(F=95.82,P<0.01).결론:전옥홍갑우대인결장암HT-29세포구유명현적증식억제화유도조망작용,기작용궤제여하조bcl-2/Bax비례유관.
Background and purpose: In recent years indirubin-3'-monoxime has been found to be capable of inhibiting some cell proliferation in vitro and in vivo studies, but human colon cancer HT-29 cells, therefore the purpose in this paper was to study the effect of indirubin-3'-monoxime on proliferation and apoptosis of HT-29 cells and its associated mechanism. Methods: HT-29 cells were treated with indirubin-3'-monoxime. The proliferative status of cells was measured by methabenzthiazuron (MTT) assay, flow cytometry (FCM) was used to measure the apoptosis rate. RT-PCR was used to measure the transcription of apoptosis suppressor gene bcl-2, survivin and apoptosis promoting gene Bar. Results: Indimbin-3'-monoxime inhibited growth of HT-29 cells in a dose-dependent and time-dependent manner (F=11.25, P<0.01). The apoptosis rate increased after the treatment by indirubin-3'-monoxime at 10 μmol/L. There were significant differences between different time groups (F=195.25, P<0.01). The transcription of survivin (F=78.75, P<0.01) and Bax (F=87.61, P<0.01) mRNA in HT-29 cells were increased; the transcription of bcl-2 was significantly decreased (F=95.82, P<0.01). Conclusion: Indirubin-3'-monoxime has obviously inhibited proliferation and induce apoptosis of colon cancer HT-29 cells, its mechanism may be related to decrease the bcl-2/Bax ratio.